



PRESS RELEASE 6/2002

October 29, 2002

Skanditek's subsidiary CMA Microdialysis AB Announces FDA Clearance.

CMA Microdialysis AB today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the CMA Cerebral Tissue Monitoring System. The system measures intra cranial glucose, lactate, and pyruvate levels as an adjunct monitor to indicate the perfusion status of brain tissue. This is a milestone in the history of the company as it opens one of the largest markets in the world.

As to the rest, we refer to enclosed press release from CMA Microdialysis AB.

Stockholm, October 29, 2002

SKANDITEK INDUSTRIFÖRVALTNING AB (publ)

For further information, please contact:

Patrik Tigerschiöld, president,
phone +46 8 614 00 20, mobile +46 70 777 71 90, e-mail patrik.tigerschiold@skanditek.se

Skanditek is an industrial holding company owning stock in Swedish unlisted and listed companies. The business concept is to be an active and long-term stockholder and to further the portfolio companies' development by providing industrial and financial competence at board and management level. The portfolio comprises 12 companies within electronics, information technology, biotechnology and services. The major holdings are in Axis (14%), LGP Telecom Holding (9%), Mydata Automation (39%), PartnerTech (40%) and Vitrolife (35%). Skanditek is listed on the Stockholm Exchange's O list.

Skanditek Industriförvaltning AB (publ)

Kungsträdgårdsgatan 18 • SE-111 47 Stockholm • Sweden • Corp No 556235-4141
Phone +46 8 614 00 20 • Fax +46 8 614 00 38 • info@skanditek.se • www.skanditek.se



Press Release 2002-10-29

CMA Microdialysis AB Announces FDA Clearance.

CMA Microdialysis AB today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the CMA Cerebral Tissue Monitoring System. The system measures intra cranial glucose, lactate, and pyruvate levels as an adjunct monitor to indicate the perfusion status of brain tissue.

The CMA Cerebral Tissue Monitoring System was released in Europe in 1996. It alerts the physician bedside to changes in brain chemistry relating to ischaemia or hypoxia, and in combination with other monitoring techniques helps diagnose secondary insults and guide therapy.

“We are delighted to get clearance for this product” says Mark Dumenil, Chief Executive Officer of CMA Microdialysis AB. “I am confident that the CMA Cerebral Tissue Monitoring System will greatly help physicians to treat brain injured patients by providing a unique bedside tool to monitor changes in brain chemistry. This is a milestone in the history of the company as it opens one of the largest markets in the world to us.” The CMA Cerebral Tissue Monitoring System is the company’s first clinical product cleared for marketing in the USA.

For more information please contact:

Mark Dumenil, CEO

Tel +46 8 470 10 90

E-mail: mark.dumenil@microdialysis.se

Ulla Ungerstedt, Communications manager

Tel +46 8 470 10 47

E-mail: ulla.ungerstedt@microdialysis.se

CMA Microdialysis AB a subsidiary of Skanditek Industriförvaltning AB (STEK.ST), designs, manufactures and sells medical devices around the world. CMA helps physicians achieve an early detection of ischaemia in vital organs through the monitoring of tissue chemistry.